Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DRMA | Common Stock | Conversion of derivative security | +44.8K | +17.58% | 299K | Aug 17, 2021 | By Hale BioVentures LLC | F1, F7 | ||
transaction | DRMA | Common Stock | Conversion of derivative security | +12.2K | +4.07% | 312K | Aug 17, 2021 | By Hale BioVentures LLC | F2, F7 | ||
transaction | DRMA | Common Stock | Conversion of derivative security | +20K | +6.42% | 332K | Aug 17, 2021 | By Hale BioVentures LLC | F3, F7 | ||
transaction | DRMA | Common Stock | Conversion of derivative security | +174K | +52.54% | 506K | Aug 17, 2021 | By Hale BioVentures LLC | F4, F7 | ||
transaction | DRMA | Common Stock | Conversion of derivative security | +27.1K | +5.36% | 533K | Aug 17, 2021 | By Hale BioVentures LLC | F5, F7 | ||
transaction | DRMA | Common Stock | Purchase | +35.7K | 35.7K | Aug 17, 2021 | By Hale Family Trust | F7, F8 | |||
holding | DRMA | Common Stock | 3.66K | Aug 17, 2021 | Direct | ||||||
holding | DRMA | Common Stock | 12.2K | Aug 17, 2021 | By Hale Trading Company LP | F7 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DRMA | Series 1d Preferred Stock | Conversion of derivative security | $0 | -302K | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 44.8K | By Hale BioVentures LLC | F1, F7 | |
transaction | DRMA | Series 1a Preferred Stock | Conversion of derivative security | $0 | -250K | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 12.2K | By Hale BioVentures LLC | F2, F7 | |
transaction | DRMA | Series 1b Preferred Stock | Conversion of derivative security | $0 | -410K | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 20K | By Hale BioVentures LLC | F3, F7 | |
transaction | DRMA | Series 1c Preferred Stock | Conversion of derivative security | $0 | -3.57M | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 174K | By Hale BioVentures LLC | F4, F7 | |
transaction | DRMA | Series 1 Preferred Stock | Conversion of derivative security | $0 | -556K | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 27.1K | By Hale BioVentures LLC | F5, F7 | |
transaction | DRMA | Series 1a Warrants | Conversion of derivative security | $0 | -62.5K | -100% | $0.00* | 0 | Aug 17, 2021 | Common Stock | 3.05K | By Hale BioVentures LLC | F6, F7 | |
transaction | DRMA | Warrant to Purchase Common Stock | Conversion of derivative security | $0 | +3.05K | $0.00 | 3.05K | Aug 17, 2021 | Common Stock | 3.05K | $20.50 | By Hale BioVentures LLC | F7 | |
transaction | DRMA | Warrant to Purchase Common Stock | Purchase | +35.7K | 35.7K | Aug 17, 2021 | Common Stock | 35.7K | $7.00 | By Hale Family Trust | F7, F8 |
Id | Content |
---|---|
F1 | The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. |
F2 | The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. |
F3 | The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. |
F4 | The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. |
F5 | The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. |
F6 | The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. |
F7 | Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
F8 | Reporting Person purchased 35,714 Units in the IPO at $7.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock. |